Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Equity Average (2016 - 2025)

Ocular Therapeutix has reported Equity Average over the past 12 years, most recently at $456.3 million for Q4 2025.

  • Quarterly results put Equity Average at $456.3 million for Q4 2025, up 36.74% from a year ago — trailing twelve months through Dec 2025 was $456.3 million (up 36.74% YoY), and the annual figure for FY2025 was $484.8 million, up 138.55%.
  • Equity Average for Q4 2025 was $456.3 million at Ocular Therapeutix, up from $282.1 million in the prior quarter.
  • Over the last five years, Equity Average for OCUL hit a ceiling of $456.3 million in Q4 2025 and a floor of $5.5 million in Q3 2023.
  • Median Equity Average over the past 5 years was $83.8 million (2021), compared with a mean of $166.3 million.
  • Biggest five-year swings in Equity Average: surged 13659.2% in 2021 and later crashed 91.21% in 2023.
  • Ocular Therapeutix's Equity Average stood at $87.7 million in 2021, then plummeted by 53.46% to $40.8 million in 2022, then increased by 21.29% to $49.5 million in 2023, then soared by 574.22% to $333.7 million in 2024, then soared by 36.74% to $456.3 million in 2025.
  • The last three reported values for Equity Average were $456.3 million (Q4 2025), $282.1 million (Q3 2025), and $285.9 million (Q2 2025) per Business Quant data.